Shares of Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $4.84 and traded as high as $4.85. Pulmatrix shares last traded at $4.50, with a volume of 7,437 shares.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmatrix in a report on Friday, October 31st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Pulmatrix currently has an average rating of “Sell”.
Get Our Latest Stock Analysis on PULM
Pulmatrix Stock Down 5.3%
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings results on Thursday, October 16th. The biotechnology company reported ($0.24) earnings per share for the quarter.
Institutional Investors Weigh In On Pulmatrix
An institutional investor recently raised its position in Pulmatrix stock. SBI Securities Co. Ltd. lifted its holdings in shares of Pulmatrix, Inc. (NASDAQ:PULM – Free Report) by 15.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,565 shares of the biotechnology company’s stock after buying an additional 8,208 shares during the period. SBI Securities Co. Ltd.’s holdings in Pulmatrix were worth $418,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.84% of the company’s stock.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- 10 Best Airline Stocks to Buy
- What’s on the Thanksgiving Table? A Stock Pick for Every Course
- Overbought Stocks Explained: Should You Trade Them?
- Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain
- How to Calculate Options Profits
- Qualcomm’s Bulls Are Running Out of Room to Be Wrong
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
